- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00895635
Evaluating Two Exercise Training Programs to Reduce Leg Pain in People With Peripheral Arterial Disease (The EXERT Study) (EXERT)
Exercise Training to Reduce Claudication: Arm Ergometry Versus Treadmill Walking
Study Overview
Status
Intervention / Treatment
Detailed Description
PAD is a condition that occurs when atherosclerotic plaque builds up in the peripheral arteries and restricts blood flow. People with PAD often experience reduced blood flow to the legs, which may cause painful leg cramping while walking, known as intermittent claudication. Claudication affects over 4 million people in the United States, and many people with this condition can walk only ½ to 2 blocks before leg pain begins to occur. Regular treadmill walking has been shown to be effective at increasing walking distance and reducing claudication in people with PAD. However, walking on a treadmill may prove difficult for some people with PAD and usually causes increased leg pain, both of which may reduce exercise frequency. Aerobic arm exercises do not cause leg pain and may be an effective way for people with PAD to improve overall cardiovascular fitness and increase the amount of exercise they do. The purpose of this study is to compare the effectiveness of a treadmill exercise program and an aerobic arm exercise program at reducing symptoms of claudication and improving walking ability in people with PAD.
This study will enroll people with PAD and claudication. At a baseline study visit, participants will complete a treadmill walking test; a blood collection; and questionnaires to assess walking status, daily activity levels, quality of life, and mood. One week after the baseline visit, participants will attend a study visit for an assessment of forearm and leg muscle blood flow and a hand-bike test that will measure upper body strength using an arm cycle ergometer. The ergometer is a device with bicycle pedals that people move using their arms. Participants will then be randomly assigned to either a treadmill exercise training program, an arm ergometry exercise program, or a control group.
Participants in the treadmill exercise training program will attend a supervised program at one of four study sites and exercise on a treadmill for 1 hour three times a week for 12 weeks. Participants in the arm ergometry exercise program will attend a supervised program at one of four study sites and exercise using an arm cycle ergometer (hand-bike) for 1 hour three times a week for 12 weeks. Participants in both groups will also receive written instructions about exercising on their own. Participants in the control group will continue to receive usual care from their regular doctor for the treatment of PAD and will be provided with written exercise instructions. Once a week for 12 weeks, participants in the control group will attend study visits to discuss any health problems.
All participants will be asked to monitor their daily exercise for 3 separate weeks during the 12-week period by wearing an accelerometer, which will measure and record physical activity. They will also record their exercise habits in a written diary. All participants will attend study visits on 2 separate days at Weeks 6 and 12 for repeat baseline testing.
From Weeks 12 to 24, all participants will be encouraged to continue to exercise on their own at least three times a week for 30 minutes. Every 4 weeks, study researchers will call participants to offer encouragement and answer questions. At Week 23, participants will again wear an accelerometer and keep an exercise diary for 1 week. All participants will attend a final study visit at Week 24 for repeat baseline testing.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has lifestyle-limiting claudication
- Able to walk on a treadmill at 2 mph
- Able to perform arm ergometry exercise
- Able to complete a 12-week exercise program
Exclusion Criteria:
- Physical activities are limited for reasons other than claudication
- Uncontrolled high blood pressure
- Uncontrolled diabetes
- Unstable coronary heart disease
- Ischemic rest pain or tissue loss
- Recent (in the 3 months before study entry) coronary or peripheral revascularization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treadmill Exercise Training
Participants will take part in a 12-week supervised treadmill exercise training program.
|
60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
|
Experimental: Arm Ergometry Exercise Training
Participants will take part in a 12-week supervised aerobic arm ergometry exercise training program.
|
60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
|
Active Comparator: Usual Care Control Group
Participants will receive usual care for PAD from their doctor.
|
Usual care for PAD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximal walking distance
Time Frame: Measured at baseline and Weeks 6, 12, and 24
|
Measured at baseline and Weeks 6, 12, and 24
|
Pain-free walking distance
Time Frame: Measured at baseline and Weeks 6, 12, and 24
|
Measured at baseline and Weeks 6, 12, and 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Limb blood flow
Time Frame: Measured at baseline and Weeks 6, 12, and 24
|
Measured at baseline and Weeks 6, 12, and 24
|
Cardiovascular function
Time Frame: Measured at baseline and Weeks 6, 12, and 24
|
Measured at baseline and Weeks 6, 12, and 24
|
Quality of life
Time Frame: Measured at baseline and Weeks 6, 12, and 24
|
Measured at baseline and Weeks 6, 12, and 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Diane J. Treat-Jacobson, PhD, RN, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0803M28683
- R01HL090854-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Diseases
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Alucent BiomedicalCompletedPeripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, PeripheralUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Alucent BiomedicalCompletedPeripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, PeripheralUnited States
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
Clinical Trials on Treadmill Exercise Training
-
Andreas R LuftRobert Bosch Medical Center; Max-Planck-Institute TuebingenCompleted
-
National Institutes of Health Clinical Center (CC)TerminatedSystemic Lupus Erythematosus | Autoimmune Disease | Rheumatic Disease | LupusUnited States
-
Flinders UniversityThe Queen Elizabeth Hospital; Flinders Medical Centre; Royal Adelaide HospitalCompletedPeripheral Arterial DiseaseAustralia
-
Kessler FoundationEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingMultiple Sclerosis | Cognitive ImpairmentUnited States
-
University of Alabama at BirminghamEMD SeronoTerminatedMultiple Sclerosis | Physical Activity | Cognitive Change | Memory ImpairmentUnited States
-
University of ZurichNot yet recruiting
-
Rush University Medical CenterTerminatedFragile X Associated Tremor-ataxia SyndromeUnited States
-
Umm Al-Qura UniversityCompletedDiabetic PolyneuropathySaudi Arabia
-
European University Miguel de CervantesHospital Clínico Universitario de ValladolidCompletedPeripheral Arterial Disease | Intermittent ClaudicationSpain
-
Umm Al-Qura UniversityCompletedDiabetic PolyneuropathySaudi Arabia